T1	intervention 0 9	Docetaxel
T4	total-participants 338 365	One hundred and seventy-six
T5	intervention-participants 623 633	Eighty-six
T6	control-participants 677 679	90
T7	outcome 740 766	Median time to progression
T8	iv-cont-median 768 771	6.5
T10	outcome 791 807	overall survival
T11	iv-cont-median 809 813	16.0
T13	iv-bin-abs 932 935	Six
T14	iv-bin-percent 937 939	7%
T15	outcome 941 959	complete responses
T16	iv-bin-abs 964 966	31
T17	iv-bin-percent 968 971	36%
T18	outcome 973 990	partial responses
T19	outcome 1016 1037	overall response rate
T20	iv-bin-percent 1038 1041	43%
T21	cv-bin-abs 1083 1084	4
T22	cv-bin-percent 1086 1090	4.4%
T23	cv-bin-abs 1115 1117	31
T24	cv-bin-percent 1119 1124	34.4%
T25	outcome 1126 1143	partial responses
T26	outcome 1186 1207	overall response rate
T27	cv-bin-percent 1208 1213	38.8%
T28	outcome 1254 1274	grade 3-4 toxicities
T29	outcome 1323 1334	neutropenia
T30	iv-bin-percent 1335 1338	82%
T31	cv-bin-percent 1342 1345	67%
T32	outcome 1347 1357	stomatitis
T33	iv-bin-percent 1358 1360	5%
T34	cv-bin-percent 1364 1367	40%
T35	outcome 1369 1388	febrile neutropenia
T36	iv-bin-percent 1389 1392	13%
T37	cv-bin-percent 1396 1399	22%
T38	outcome 1405 1414	infection
T39	iv-bin-percent 1415 1417	2%
T40	cv-bin-percent 1421 1423	7%
T41	iv-bin-abs 1435 1438	one
T42	outcome 1448 1471	treatment-related death
T43	cv-bin-abs 1497 1501	five
T3	eligibility 366 399	metastatic breast cancer patients
T2	control 13 44	5-fluorouracil plus vinorelbine
T9	cv-cont-median 775 785	5.1 months
T12	cv-cont-median 817 828	15.0 months
T44	outcome 1092 1110	complete responses
